PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Rhea-AI Summary
PolyPid (Nasdaq: PYPD) reported second-quarter 2026 results and key regulatory and commercial milestones for D-PLEX₁₀₀ for prevention of surgical site infections in abdominal colorectal surgery.
The FDA accepted the D-PLEX₁₀₀ NDA with Priority Review and set a PDUFA goal date of November 28, 2026, about one quarter earlier than PolyPid’s prior guidance. No filing review issues were identified. PolyPid also signed an exclusive U.S. and Canada commercialization agreement with Azurity Pharmaceuticals, unlocking $30 million in upfront and near-term milestone payments following NDA acceptance and making the company eligible for up to approximately $320 million in total milestones plus tiered royalties from mid-teen to mid-twenties percentages. Azurity will fund additional clinical development for potential label expansion, while PolyPid retains ex-U.S./Canada commercial rights and global manufacturing.
For Q2 2026, PolyPid reported a net loss of $7.8 million ($0.35 per share) versus $10.0 million ($0.78 per share) a year earlier, with operating expenses modestly lower. As of June 30, 2026, cash and cash equivalents were $6.6 million, excluding the $30 million from Azurity. According to PolyPid, its current cash plus expected proceeds from the Azurity agreement should fund operations into 2028.
Positive
- FDA Priority Review for D-PLEX₁₀₀ NDA; PDUFA goal date November 28, 2026, about one quarter earlier than prior guidance
- Azurity partnership securing $30 million in upfront and near-term milestones, with up to approximately $320 million in total potential milestone payments
- Tiered royalties from mid-teen to mid-twenties percentages on U.S. and Canada D-PLEX₁₀₀ sales, plus manufacturing revenue via agreed transfer price
- Azurity-funded label expansion for additional surgical site infection indications in U.S. and Canada, while PolyPid retains ex-U.S./Canada commercial rights and global manufacturing
- Reduced net loss Q2 2026 net loss $7.8 million versus $10.0 million in Q2 2025; six-month net loss $15.6 million versus $18.2 million a year earlier
- Lower operating expenses G&A expenses decreased to $1.3 million in Q2 2026 from $2.5 million in Q2 2025; six-month G&A down to $2.9 million from $3.7 million
Negative
- Continuing losses Q2 2026 net loss $7.8 million and six-month net loss $15.6 million, with accumulated deficit reaching $317.1 million
- Cash position June 30, 2026 cash and cash equivalents of $6.6 million versus $12.9 million cash, cash equivalents and short-term deposits at December 31, 2025, excluding later $30 million from Azurity
- Equity decline shareholders’ equity fell to $5.4 million at June 30, 2026 from $11.0 million at year-end 2025, while shares outstanding increased from 18.2 million to 20.3 million
News Explained
PolyPid reported 20,311,766 issued and outstanding ordinary shares at
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 13 | Q1 2026 earnings | Positive | -7.5% | Regulatory progress and partnership discussions accompanied a negative 24-hour reaction. |
| Feb 11 | FY 2025 earnings | Positive | -1.3% | Positive FDA feedback and development progress accompanied a negative 24-hour reaction. |
| Nov 12 | Q3 2025 earnings | Positive | -0.3% | Regulatory preparation and trial progress accompanied a slightly negative 24-hour reaction. |
| Aug 13 | Q2 2025 earnings | Positive | +2.0% | Positive Phase 3 results and extended cash runway accompanied a positive reaction. |
| May 14 | Q1 2025 earnings | Positive | +7.0% | Phase 3 enrollment completion and expected top-line results accompanied a positive reaction. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Comparable earnings releases produced mixed reactions, with positive operational updates diverging from the stock reaction in three of five events.
Key Terms
nda regulatory
pdufa regulatory
marketing authorization application regulatory
cmc technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance
Exclusive U.S. and Canada Commercialization Partnership with Azurity Pharmaceuticals;
Potential U.S. Commercial Launch of D-PLEX₁₀₀ by Azurity Targeted for Early 2027
Conference Call Scheduled for Today at 8:30 AM ET
PETACH TIKVA, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today provided a corporate update and reported financial results for the three and six months ended June 30, 2026.
Recent Corporate Highlights:
- Completed NDA Submission for D-PLEX₁₀₀ and Received FDA Acceptance with Priority Review:
- Completed its New Drug Application ("NDA") submission to the U.S. Food and Drug Administration ("FDA") for D-PLEX₁₀₀ for the prevention of surgical site infections ("SSIs") in patients undergoing abdominal colorectal surgery, supported by positive results from the pivotal Phase 3 SHIELD II trial, which met its primary endpoint and all key secondary endpoints and demonstrated a
60% relative risk reduction in SSIs compared to standard of care (p=0.0013). - Subsequent to quarter end, on July 27, 2026, the FDA accepted D-PLEX₁₀₀ NDA submission and granted Priority Review, with a Prescription Drug User Fee Act ("PDUFA") goal date of November 28, 2026, approximately one quarter ahead of the Company's previously communicated first quarter 2027 guidance. The FDA did not identify any filing review issues in its acceptance communications.
- Completed its New Drug Application ("NDA") submission to the U.S. Food and Drug Administration ("FDA") for D-PLEX₁₀₀ for the prevention of surgical site infections ("SSIs") in patients undergoing abdominal colorectal surgery, supported by positive results from the pivotal Phase 3 SHIELD II trial, which met its primary endpoint and all key secondary endpoints and demonstrated a
- Exclusive U.S. and Canada Commercialization Partnership with Azurity Pharmaceuticals:
- Following the end of the quarter, on July 17, 2026, PolyPid entered into a commercial partnership agreement with Azurity Pharmaceuticals ("Azurity"), a privately held global specialty pharmaceutical company with a first-in-class commercial model, deep experience in specialty and hospital-based therapies with more than 50 medicines across 10 therapeutic areas. Azurity has an experienced commercial launch and execution team launching more than one product each year on average in the last several years.
- Following the FDA's July 27, 2026 NDA acceptance, PolyPid has achieved the milestones required for the
$30 million in upfront and near-term milestone payments from Azurity. - Under the partnership, PolyPid is eligible to receive up to approximately
$320 million in total upfront and milestone payments, inclusive of the$30 million confirmed to date, structured across a defined series of regulatory, launch, and sales milestones aligned with the anticipated U.S. and Canada commercialization of D-PLEX₁₀₀. - In addition to and separate from the milestone payments, PolyPid is entitled to tiered royalties from mid-teen to mid-twenties percentages on sales in the U.S. and Canada. Additionally, PolyPid will manufacture and supply D-PLEX₁₀₀ to Azurity for an agreed transfer price, further strengthening the Company’s expected revenues from product sales.
- As part of the collaboration, Azurity will fund clinical development to support potential label expansion of D-PLEX₁₀₀ in the U.S. and Canada to additional SSI indications beyond abdominal surgery, potentially expanding the future addressable market.
- PolyPid retains commercial rights outside the U.S. and Canada, manufacturing rights worldwide, and full ownership of its Kynatrix™ technology and associated pipeline.
- Advancing EU Regulatory Submission:
- PolyPid remains on track for the previously announced third quarter 2026 submission of its Marketing Authorization Application ("MAA") to the European Medicines Agency ("EMA") for D-PLEX₁₀₀ under the Centralized Procedure on the basis of therapeutic innovation. During the second quarter of 2026, the Company held productive and positive meetings with the EMA Rapporteur and Co-Rapporteur, aligning on the timeline and requirements for the planned MAA submission.
- Advancing Kynatrix™ Pipeline Beyond D-PLEX₁₀₀:
- Beyond D-PLEX₁₀₀, PolyPid continues to advance its proprietary Kynatrix™ technology through additional pipeline programs, including its long-acting metabolic program and additional infection opportunities beyond prevention. These programs are being designed to leverage the Company's established Kynatrix™ technology capabilities, existing clinical and chemistry, manufacturing and controls (“CMC”) foundation, and known active pharmaceutical ingredient safety profile.
- Upcoming Expected Milestones:
- PDUFA goal date for the D-PLEX₁₀₀ NDA of November 28, 2026.
- MAA submission to the EMA for D-PLEX₁₀₀ under the Centralized Procedure in the third quarter of 2026.
- Potential U.S. commercial launch of D-PLEX₁₀₀ in early 2027.
"The second quarter of 2026 and the first few weeks of the third quarter completed PolyPid's transition into a commercial-stage company, with the acceptance by the FDA with Priority Review of our NDA submission for D-PLEX₁₀₀, with no filing review issues and a PDUFA goal date meaningfully ahead of the guidance we have previously communicated," said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. "In parallel, the U.S. and Canada commercial partnership we entered into in July, together with the immediate
Financial Results for the Three Months Ended June 30, 2026
- Research and development expenses for the three months ended June 30, 2026, were
$6.1 million , compared to$6.2 million in the same three-month period of 2025. Research and development activity in the second quarter of 2026 primarily reflects ongoing NDA-related activities and continued commercial readiness preparation. - General and administrative expenses for the three months ended June 30, 2026, were
$1.3 million , compared to$2.5 million for the same period of 2025. The decrease was primarily due to the decrease of non-cash expenses related to performance-based options ("PSUs") following the positive Phase 3 SHIELD II topline results, which triggered the vesting of those PSUs. - Marketing and business development expenses for the three months ended June 30, 2026, were
$0.5 million , compared to$0.7 million for the same period of 2025. - For the three months ended June 30, 2026, the Company had a net loss of
$7.8 million , or$(0.35) per share, compared to a net loss of$10.0 million , or$(0.78) per share, in the three-month period ended June 30, 2025.
Financial Results for the Six Months Ended June 30, 2026
- Research and development expenses for the six months ended June 30, 2026, were
$11.9 million , compared to$12.3 million in the same six-month period of 2025. The decrease primarily reflects the completion of the SHIELD II Phase 3 trial and the Company's transition toward regulatory submission and commercial readiness activities. - General and administrative expenses for the six months ended June 30, 2026, were
$2.9 million , compared to$3.7 million for the same period of 2025. The decrease was primarily due to the decrease of non-cash PSU vesting expenses. - Marketing and business development expenses for the six months ended June 30, 2026, were
$0.9 million , compared to$1.0 million for the same period of 2025. - For the six months ended June 30, 2026, the Company had a net loss of
$15.6 million , or$(0.70) per share, compared to a net loss of$18.2 million , or$(1.48) per share, in the six-month period ended June 30, 2025.
Balance Sheet Highlights
- As of June 30, 2026, the Company had cash and cash equivalents of
$6.6 million , compared to cash, cash equivalents and short-term deposits of$12.9 million on December 31, 2025, not including$30 million in upfront and near-term milestone payments from Azurity, substantially strengthening the Company's balance sheet as it approaches the November 28, 2026 PDUFA goal date and prepares for a potential U.S. commercial launch of D-PLEX₁₀₀ in early 2027. - The Company believes that its current cash position, together with its expected proceeds from its recently announced commercialization agreement, as well as future potential proceeds, will be sufficient to fund operations into 2028 and through several significant upcoming potential milestones.
Conference Call Dial-In & Webcast Information:
| Date: | Wednesday, August 12, 2026 |
| Time: | 8:30 AM Eastern Time |
| Conference Call: | https://register-conf.media-server.com/register/BI9a8ec61eabe249f6a1e931836c819ce8 |
| Webcast: | https://edge.media-server.com/mmc/p/3mbsv986 |
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid’s lead product, D-PLEX₁₀₀, successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections. Guided by a commitment to precision and innovation, PolyPid is redefining how therapies perform and raise the standard of patient care. For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.
Forward-looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the anticipated timing of the FDA's review and potential approval of the D-PLEX₁₀₀ NDA, including the PDUFA goal date; the anticipated timing of the Company's planned MAA submission to the EMA for D-PLEX₁₀₀; the timing, receipt and amount of regulatory, launch and other milestone payments and royalties under the Company's agreement with Azurity; the potential label expansion of D-PLEX₁₀₀ and its funding by Azurity; the anticipated timing of a potential U.S. commercial launch of D-PLEX₁₀₀ by Azurity; the Company’s belief that it is potentially in the strongest financial position in the Company’s history, with no immediate financing needs ; the Company’s belief that its current cash position, together with its expected proceeds from its recently announced commercialization agreement, as well as future potential proceeds, will be sufficient to fund operations into 2028 and through several significant upcoming potential milestones; the therapeutic and commercial potential of D-PLEX₁₀₀; and the Company's plans to advance Kynatrix™ technology through additional pipeline programs, including its long-acting metabolic program and additional infection opportunities beyond prevention. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission, including, but not limited to, the risks detailed in the Company's Annual Report on Form 20-F filed on February 25, 2026. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.
Company Contact:
PolyPid Ltd.
Ori Warshavsky
908-858-5995
IR@Polypid.com
Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
polypid@arxhq.com
| INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) | |||||
| U.S. dollars in thousands | |||||
| June 30, | December 31, | ||||
| 2026 | 2025 | ||||
| ASSETS | |||||
| CURRENT ASSETS: | |||||
| Cash and cash equivalents | $ | 6,563 | $ | 6,402 | |
| Restricted deposits | 207 | 193 | |||
| Short-term deposits | - | 6,531 | |||
| Pre-launch inventories | 1,359 | 1,106 | |||
| Prepaid expenses and other current assets | 757 | 995 | |||
| Total current assets | 8,886 | 15,227 | |||
| LONG-TERM ASSETS: | |||||
| Property and equipment, net | 4,613 | 5,094 | |||
| Operating lease right-of-use assets | 1,408 | 1,675 | |||
| Long-term deposits | 327 | 311 | |||
| Total long-term assets | 6,348 | 7,080 | |||
| Total assets | $ | 15,234 | $ | 22,307 | |
| INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) | |||||||
| U.S. dollars in thousands (except share and per share data) | |||||||
| June 30, | December 31, | ||||||
| 2026 | 2025 | ||||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | |||||||
| CURRENT LIABILITIES: | |||||||
| Trade payables | $ | 1,662 | $ | 2,856 | |||
| Accrued expenses and other current liabilities | 3,651 | 2,734 | |||||
| Current maturities of long-term debt | - | 988 | |||||
| Current maturities of operating lease liabilities | 1,290 | 1,161 | |||||
| Total current liabilities | 6,603 | 7,739 | |||||
| LONG-TERM LIABILITIES: | |||||||
| Deferred revenues | 2,548 | 2,548 | |||||
| Long-term operating lease liabilities | 282 | 647 | |||||
| Other liabilities | 413 | 400 | |||||
| Total long-term liabilities | 3,243 | 3,595 | |||||
| COMMITMENTS AND CONTINGENT LIABILITIES | |||||||
| SHAREHOLDERS' EQUITY: | |||||||
| Ordinary shares, no par value - | - | - | |||||
| Authorized: 107,800,000 shares at June 30, 2026 and December 31, 2025; | |||||||
| Issued and outstanding: 20,311,766 and 18,204,002 shares at June 30, 2026 and December 31, 2025, respectively | |||||||
| Additional paid-in capital | 322,465 | 312,473 | |||||
| Accumulated deficit | (317,077 | ) | (301,500 | ) | |||
| Total shareholders' equity | 5,388 | 10,973 | |||||
| Total liabilities and shareholders' equity | $ | 15,234 | $ | 22,307 | |||
| INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) | ||||||||||||
| U.S. dollars in thousands (except share and per share data) | ||||||||||||
| Six Months Ended | Three Months Ended | |||||||||||
| June 30, | June 30, | |||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||
| Operating expenses: | ||||||||||||
| Research and development | $ | 11,881 | $ | 12,332 | $ | 6,125 | $ | 6,215 | ||||
| Marketing and business development | 873 | 989 | 459 | 700 | ||||||||
| General and administrative | 2,855 | 3,661 | 1,265 | 2,488 | ||||||||
| Operating loss | 15,609 | 16,982 | 7,849 | 9,403 | ||||||||
| Loss on extinguishment of debt | - | 512 | - | - | ||||||||
| Financial expense (income), net | (38 | ) | 687 | (6 | ) | 521 | ||||||
| Loss before income tax | 15,571 | 18,181 | 7,843 | 9,924 | ||||||||
| Income tax expenses | 6 | 64 | 6 | 53 | ||||||||
| Net loss | $ | 15,577 | $ | 18,245 | $ | 7,849 | $ | 9,977 | ||||
| Basic and diluted loss per ordinary share | $ | 0.70 | $ | 1.48 | $ | 0.35 | $ | 0.78 | ||||
| Weighted average number of ordinary shares used in computing basic and diluted loss per share | 22,280,991 | 12,298,113 | 22,637,513 | 12,841,621 | ||||||||
